Emerging data suggest this peptide, a dual agonist targeting both the gut-brain axis and GIP , may offer a promising development for weight loss . Early human investigations have demonstrated https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide